Lorca

Psoriatic arthritis (PsA) is a type of arthritis that causes joint swelling and stiffness and is often seen in people with the skin condition psoriasis. It results from an overactive immune system attacking healthy tissue. This research aims to describe the long-term use and effectiveness of risankizumab (RZB) compared to other advanced treatments for managing PsA in everyday clinical care. The study is not conducted in the United States but will take place in about 15 countries and include between 900 and 1200 adult participants. Participants will be assigned in a 2 to 1 ratio to receive either risankizumab or other advanced therapeutic agents. The treatments will be given following usual medical guidelines, including approved dosing and indications, as determined by local regulations and professional standards. All study visits will occur during routine clinical care with no extra burden on participants. Participants will be followed and monitored for 24 months to observe treatment persistence. During the study, participants will continue their regular clinical visits without additional procedures or tests required by the study. Researchers will measure how many participants continue their prescribed treatment over the 24-month period. The study focuses on real-world treatment patterns and outcomes in patients with active PsA who have previously shown an inadequate response or intolerance to certain medications. Safety monitoring will align with routine clinical practice throughout the study duration.

Researchers are collecting detailed information about patients with venous thromboembolism (VTE), which includes blood clots in veins such as deep-vein thrombosis and pulmonary embolism. The project aims to improve doctors' understanding of VTE, especially in patients often excluded from clinical trials, like pregnant women, elderly individuals, cancer patients, and those with other complex health issues. The goal is to reduce deaths, clot recurrence, bleeding problems, and artery-related events by sharing this knowledge widely. The study involves gathering extensive data on each patient's health status, treatments, and outcomes during the first three months of therapy. This registry is available online to help doctors quickly find information on patients with similar medical profiles and make informed decisions about managing high-risk individuals. There are no specific interventions being tested; instead, the focus is on collecting real-world patient data. Participants provide informed consent and are followed for at least three years to monitor for new clot events and complications. Researchers track recurrences of VTE, bleeding episodes, and deaths, aiming to create tools that predict which patients are most at risk for problems. This ongoing data collection supports improving care and guiding treatment decisions for diverse patient groups over time.

Researchers are evaluating the use of long-acting Cabotegravir (CAB) and Rilpivirine (RPV) in adults aged 60 years and older who are living with HIV-1 and have controlled viral levels. This study aims to confirm that the effectiveness and safety of CAB LA + RPV LA in older adults are comparable to those in younger patients. Additionally, the study monitors metabolic and liver health markers, as older adults may have more related health issues. Psychological and social well-being is also considered due to the potential impact of social stigma on this group. Participants receive an initial induction treatment with intramuscular injections of CAB LA 600 mg and RPV LA 900 mg at months 1 and 2. Following this, they receive the same injections every two months for a total duration of 24 months. This long-acting injectable treatment replaces their stable oral antiretroviral therapy regimen. Throughout the study, researchers assess viral load to confirm that HIV remains controlled with plasma HIV-1 RNA levels below 50 copies/mL. Participants are regularly monitored for metabolic and hepatic parameters, and adherence to treatment is tracked. The study also evaluates psychosocial aspects and overall safety during the two-year period to better understand treatment outcomes in this older population.